Looking Into Epizyme’s Return On Capital Employed
According to Benzinga Pro data, during Q2, Epizyme (NASDAQ:EPZM) posted sales of $27.53 million. Earnings were up 35.6%, but Epizyme still reported an overall loss of $35.74 million.
Epizyme Granted U.S. Patent #11,370,781 Combination therapy for treating cancer
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5571&f=G&l=50&d=PTXT&p=112&S1=20220628&OS=20220628&RS=20220628
Cowen & Co. Downgrades Epizyme to Market Perform, Announces $1.5 Price Target
Cowen & Co. analyst Joseph Thome downgrades Epizyme (NASDAQ:EPZM) from Outperform to Market Perform and announces $1.5 price target.
This Healthcare Stock Jumps Around 188%, Here’s 83 Biggest Movers From Yesterday
Gainers
Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade.
Why Is NeuroSense Therapeutics Surging by 70%? 46 Stocks Moving In Monday’s Mid-Day Session
Gainers
Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 87.3% to $0.6965 amid the Supreme Court overturning Roe V Wade.
The Daily Biotech Pulse: CHMP Backs AstraZeneca’s Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
Here's a roundup of top developments in the biotech space over the last 24 hours:
Why Epizyme Shares Are Soaring Today
Epizyme Inc (NASDAQ: EPZM) shares are trading higher Monday after the company announced it entered into a definitive agreement to be acquired by Ipsen.
Epizyme + 20 Stocks Moving In Monday’s Pre-Market Session
Gainers
Tenax Therapeutics, Inc. (NASDAQ: TENX) rose 90.1% to $0.59 in pre-market trading after dipping more than 46% on Friday.
Ipsen to Acquire Epizyme for $1.45/Share in Cash, Plus a Contingent Value Right of $1.00/Share
Ipsen (Euronext: IPN; ADR: IPSEY) and Epizyme (Nasdaq: EPZM) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme.
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
Gainers
Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash.